Core Insights - GSK plc (NYSE:GSK) is identified as one of the best undervalued European stocks to consider for investment [1] - The company reported fourth-quarter earnings that exceeded analyst expectations, with earnings per share at $0.6989, which is 9.58% higher than the forecast of $0.6378, and revenue at $11.81 billion, surpassing the forecast of $11.36 billion by 3.96% [1] Financial Performance - Specialty Medicines experienced a growth of 17%, while Oncology sales surged by 43% compared to the same quarter last year [2] - GSK has provided optimistic guidance for 2026, projecting sales growth of 3-5%, with core operating profit and earnings per share expected to rise by 7-9%, indicating potential margin expansion [3] Company Overview - GSK plc is a UK-based global biopharmaceutical company focused on researching, developing, and selling medicines and vaccines for various health conditions, including infectious diseases, HIV, respiratory issues, cancer, and immune-related disorders [4]